Beigene: JP Morgan Raises PT to $345, Maintains Overweight Rating

Beigene: JP Morgan Raises PT to $345, Maintains Overweight Rating

JPMorgan Chase has increased its price target for BeOne Medicines (ONC) from $321 to $345, maintaining an Overweight rating for the stock. This adjustment comes after the passage of the One Big Beautiful Bill, which alters certain regulatory dynamics. Specifically, the bill exempts drugs with multiple orphan indications, such as Brukinsa, from being subject to price negotiations under the Inflation Reduction Act. This legislative change is viewed favorably by analysts, improving the valuation outlook for ONC [1].

Based on the one-year price targets offered by 23 analysts, the average target price for BeOne Medicines Ltd (ONC) is $277.93 with a high estimate of $376.00 and a low estimate of $207.00. The average target implies a downside of 0.44% from the current price of $279.16. More detailed estimate data can be found on the BeOne Medicines Ltd (ONC) Forecast page [1].

Based on the consensus recommendation from 24 brokerage firms, BeOne Medicines Ltd's (ONC) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell [1].

Based on GuruFocus estimates, the estimated GF Value for BeOne Medicines Ltd (ONC) in one year is $436.09, suggesting an upside of 56.22% from the current price of $279.16. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the BeOne Medicines Ltd (ONC) Summary page [1].

References:
[1] https://www.gurufocus.com/news/2983849/jpmorgan-boosts-beone-medicines-onc-price-target-to-345-onc-stock-news